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Background: A variety of shared care models have been developed which aim to stratify 35 
glaucoma patients according to risk of disease progression. However, there is limited published 36 
data on the rate of glaucoma progression in the hospital versus community setting.  Here we 37 
aimed to compare rates of glaucomatous visual field progression in the Cambridge Community 38 
Optometrist Glaucoma Scheme (COGS) and Addenbrooke's Hospital Glaucoma Clinic (AGC). 39 
 40 
Methods: A retrospective comparative cohort review was performed. Patients with 5 or more 41 
visual field tests were included. Zeiss Forum software was used to calculate the MD 42 
progression rate (dB/year). Loss of sight years (LSY) were also calculated for both COGS and 43 
AGC. 44 
 45 
Results: 8465 visual field tests from 854 patients were reviewed. 362 eyes from the AGC 46 
group and 210 eyes from COGS were included. The MD deterioration rate was significantly 47 
lower in the COGS patients compared with the AGC group (-0.1 dB/year vs -0.3 dB/year; 48 
p<0.0001). No patients in the COGS group were predicted to become blind within their lifetime 49 





Conclusion: This service evaluation shows that COGS is an effective scheme to stratify lower 52 
risk glaucoma patients, increasing the capacity within HES. COGS patients have a lower rate 53 
of visual field deterioration compared to AGC patients. Effective communication between 54 
community and tertiary schemes is essential to facilitate transfer of patients requiring further 55 
hospital management reliably and efficiently, with the potential for low risk patients to be 56 




The lack of capacity in the United Kingdom’s hospital eye services (HES) for glaucoma 61 
patients has been highlighted in a recent report from the Healthcare Safety Investigation Branch 62 
and the award of £3.2 million in compensation by the National Health Service (NHS) to a 34 63 
year old glaucoma patient who went blind due to follow-up delays(1). An estimated 22 people 64 
a month suffer severe or permanent loss of sight due to delays in follow-up appointments, and 65 
this has also been attributed to insufficient capacity within HES(2). The COVID-19 pandemic 66 
has further accelerated the need to manage patients away from HES.  67 
Referral rates for glaucoma suspects and ocular hypertensives also increased following the 68 
publication of the initial National Institute for Health and Care Excellence (NICE) guidelines 69 
for primary open angle glaucoma (POAG) and ocular hypertension (OHT)(3). The Royal 70 
College of Ophthalmologists (RCOphth) issued national guidance to address the anticipated 71 
lack of capacity associated with increased referral rates, recommending that a proportion of 72 
glaucoma-related NHS HES attendances were contracted to community-based practitioners(4). 73 




glaucoma to reduce the HES workload; a case mix representing over 30% of HES glaucoma-75 
related visits and over 1 million people in England.  76 
 77 
A variety of shared care models have been developed in the UK and overseas which aim to 78 
stratify glaucoma patients according to risk of disease progression(5–10). Often, one goal in 79 
such schemes is for hospital-based care to be focused on those at higher risk of disease 80 
progression where more aggressive treatment may be required to prevent visual disability(11), 81 
with lower risk patients managed outside the hospital according to available local expertise and 82 
resources. However, there is limited published data on the rate of glaucoma progression in 83 
hospital versus community setting for many of these schemes.  In the current study, our aim 84 
was to conduct a service evaluation to compare rates of glaucomatous visual field progression 85 
and loss of sight years in the Cambridge Community Optometrist Glaucoma Scheme (COGS) 86 
and Addenbrooke's Hospital Glaucoma Clinic (AGC). The AGC is a tertiary referral centre, 87 
but as there is no other hospital serving the local population, the glaucoma clinic for adult 88 
patients also functions in a very similar way to other district general hospitals in addition to 89 
providing specialist services. We therefore feel that our study is applicable to both secondary 90 
and tertiary level services.  91 
  92 
The Cambridge Community Optometrist Glaucoma Scheme (COGS) 93 
 COGS was established in 2010 and initially used for referral refinement(10). All new referrals 94 
to AGC were triaged by a glaucoma specialist nurse into high risk and low risk categories. 95 
Those deemed low risk (intraocular pressure (IOP) below 30mmHg or a field defect suspicious 96 
of glaucoma or an optic disc suspicious of glaucoma) were assessed in COGS. In 2012, the 97 
scheme expanded to monitor ocular hypertensive and glaucoma suspect patients (treated and 98 




primary open angle glaucoma, considered low risk for vision loss. In 2019 the scheme widened 100 
the inclusion criteria to include more complex and moderate risk glaucoma cases.  The current 101 
risk stratification guideline used to determine if a patient is suitable for COGS follow-up is 102 
outlined in Table 1 below. This guideline is based on an agreed empiric assessment of risk, in 103 
conjunction with local stakeholders and clinicians. Changes to the National Institute for Health 104 
and Care Excellence guidelines for the diagnosis and management in glaucoma in 2017, 105 
including an increased emphasis on optic disc imaging which was not available uniformly in 106 
our community clinics, led to a modification of the scheme such that all newly referred patients 107 
are now first assessed in AGC with baseline imaging and then referred to the COGS scheme if 108 
appropriate.  109 
 110 
Patients are examined according to a local protocol using equipment standardised to AGC. Due 111 
to a lack of uniform capacity for ocular coherence tomography (OCT) in community optometry 112 
practices participating in COGS during the period reported, OCT was not mandated in the 113 
COGS clinical assessment, but was performed in the AGC.  Participating optometrists 114 
complete training in glaucoma under the supervision of a consultant ophthalmologist. They are 115 
also required to complete the College of Optometrists Professional Certificate in 116 
Glaucoma(12). 117 
 118 
Community optometrists have remote access to hospital electronic records and enter all their 119 
results in real time. Findings are summarised using a standardised template. All results are 120 
reviewed by a consultant ophthalmologist or hospital optometrist within four weeks of the 121 
community glaucoma assessment.  An outcome letter is generated by the reviewing clinician 122 






A retrospective comparative cohort review was performed of patients attending the AGC clinic 126 
or COGS clinic. All patients had SITA-standard automated perimetry performed with the 127 
Humphrey Field Analyzer (HFA, Carl Zeiss Meditec, Dublin, Calif.) using the 24-2 full-128 
threshold programme with a Goldmann size III stimulus and appropriate refractive correction.  129 
Patients that had either had one or two eyes with 5 or more SITA-standard 24-2 visual field 130 
tests were included in the analysis. All patients from the COGS service since its inception in 131 
2010 to 2019 and a similar cohort from the AGC group were analysed. Data for each eye was 132 
processed separately where both eyes were included. The Zeiss Forum software was used to 133 
extract the data and calculate the MD progression rate (dB/year) using Guided Progression 134 
Analysis. Graphpad Prism software was used for statistical analysis. The D'Agostino-Pearson 135 
test was used to evaluate whether the distribution of continuous variables was normal.  The 136 
descriptive statistics for non-normally distributed variables (number of visual field tests, 137 
follow-up, mean deviation rate of progression, loss of sight years) are presented as median 138 
(25th-75th percentiles) unless otherwise specified. The Mann-Whitney test was used to compare 139 
non-normally distributed independent variables between groups. Loss of sight year (LSY) 140 
analysis was performed by estimating the number of years each patient would develop bilateral 141 
VF loss worse than MD of −22 dB in their predicted remaining lifetime as previously 142 
described(13).  143 
 144 
RESULTS 145 
8465 visual field tests from a total of 854 patients were reviewed.  362 eyes from the AGC 146 
group and 210 eyes from the COGS group met the eligibility criteria of 5 or more SITA-147 
standard 24-2 visual field tests. All diagnoses and visual field tests performed were included 148 





The median MD rates highlighted worsening vision over time in both groups (Table 3). 151 
However, the rate of deterioration was significantly lower in the COGS patients compared with 152 
the AGC group. (-0.1 dB/year vs -0.3 dB/year; p<0.0001).  153 
 154 
COGS followed up the majority of patients progressing between 0 to 1 dB per year. 14.3% of 155 
patients in the AGC were progressing at a rate greater than 1 dB/year compared to 6.2% in the 156 
COGS group. Of the 13 patients in the COGS service that were progressing at greater than 1 157 
dB/year, 11 (87%) had additional non-glaucoma diagnoses that would also affect the visual 158 
field. There were no patients in the COGS group deteriorating at rates greater than 3 dB/year. 159 
 160 
In general, ocular comorbidities that may have affected the visual field were relatively similar 161 
across both groups including age-related macular degeneration (4.4% in AGC vs 2.9% in 162 
COGS) and diabetic retinopathy (1.1% in AGC vs 3.8% in COGS). 32.9% of AGC patients 163 
had undergone cataract surgery vs 21.4% in COGS. 164 
 165 
We also evaluated the visual field loss at the end of the study (Figure 1A-C). We defined early 166 
glaucoma as a visual field defect corresponding to a MD of -6 dB or better, moderate glaucoma 167 
as an MD between -6 and -12 dB, severe glaucoma as an MD between -12 and -20 dB and end-168 
stage glaucoma as an MD of -20 dB or worse. COGS had a greater proportion of patients with 169 
early glaucoma (56.4% in AGC vs 72.9% in COGS) while AGC had a greater proportion of 170 
patients with moderate glaucoma (26.5% in AGC vs 13.8% in COGS). Interestingly, there was 171 
a similar percentage of patients with severe glaucoma in both groups (11% in AGC vs 10% in 172 
COGS). The proportion of patients with end-stage glaucoma in AGC was approximately 173 




not have glaucomatous visual field loss at entry was 16% in AGC and 19.5% in COGS. At the 175 
end point of the study, these proportions were 10.2% in AGC and 18.1% in COGS. There was 176 
a significant correlation between the visual field loss observed at the end of the study and the 177 
rate of MD progression across both groups although the correlation was weaker for COGS 178 
patients (Spearman’s correlation coefficient r = 0.60 for AGC vs 0.33 for COGS; p<0.0001in 179 
both groups). No significant correlation was seen between the initial MD and rate of MD 180 
progression (Spearman’s correlation coefficient r = -0.07 for AGC; p=0.16 vs r = 0.03 for 181 
COGS; p-0.66) or the baseline severity between both groups (p=0.15). Figure 1D shows the 182 
relationship between initial MD and rate of MD progression across both groups.  183 
 184 
The loss of sight year (LSY) analysis was performed in patients from whom data from both 185 
eyes was available (Figure 2). This showed a median of 0 years (0-0) in both groups, suggesting 186 
that the majority of patients in either group were unlikely to become blind during the course of 187 
their lifetime. There were no rapid progressors in the COGS group and no patients in the COGS 188 
group were at risk of becoming blind within their lifetime. Fifteen patients were at risk in the 189 
AGC group. Weak correlation was seen between the presenting MD and LSY (Spearman’s 190 
correlation coefficient r = -0.13; p=0.04). 191 
 192 
DISCUSSION 193 
COGS was established to help streamline the management of glaucoma in Cambridge, aiming 194 
to concentrate higher risk glaucoma patients in AGC and lower risk patients in community 195 
clinics. In the current study, there was a significantly greater rate of MD progression in the 196 
AGC compared to COGS. No patients were identified as at risk of becoming blind in their 197 
lifetime in the COGS group and all rapid progressors (progressing at greater than 3 dB/year) 198 




(between 0 to 1 dB/year) and 11 of 13 patients in the COGS group progressing at greater than 200 
1 dB/year had other pathologies such as cataract, or coexisting neurological or retinal 201 
pathology. One patient from the COGS group progressing at greater than 1 dB/year also 202 
requested to remain under the COGS service rather transfer back to AGC.  203 
 204 
Ongoing capacity pressures within AGC have led to an increase in the proportion of patients 205 
with more advanced glaucoma that are followed within the community scheme over time.  This 206 
highlights the need for effective communication channels to identify patients requiring further 207 
hospital management reliably and efficiently. A recent internal audit conducted at the end of 208 
the period of analysis demonstrated that 41% of all patients (45% of moderate risk patients) 209 
monitored in COGS were deemed to be unstable at virtual review and required an AGC 210 
appointment. Upon review in hospital, the majority of those patients (72%) were correctly 211 
identified as unstable and required a change of treatment or closer AGC monitoring. 212 
 213 
The widening scope of patients managed in COGS could be considered a strength of the 214 
scheme. Rather than exclude this higher risk cohort from community clinics, strategies 215 
continue to be developed to manage these patients in the community. The planned transition to 216 
virtual amendment of treatment changes by the clinical reviewer with subsequent COGS follow 217 
up has the potential to reduce the AGC referral rate. Our risk stratification is based on empiric 218 
assessment in conjunction with local stakeholders and clinicians.  Alternative stratification 219 
methods also include recent tools published by the Royal College of Ophthalmologists 220 
(RCOphth) and UK and Eire Glaucoma Society (UKEGS)(14) and the UK Ophthalmology 221 
Alliance (UKOA)(15) although it is likely that these guidelines will be tailored according to 222 





LSY analysis was used to help assess the safety of following patients predicted to be at low 225 
risk in primary care rather than hospital glaucoma clinics. However, it is important to remember 226 
that patients can also suffer a reduced quality of life with an increased risk of falls and other 227 
comorbidity due to visual loss before blindness and therefore LSY should not be used as a tool 228 
in isolation and the results should be interpreted with caution.  229 
 230 
Streamlining and stratifying pathways to facilitate the management of an increasing glaucoma 231 
population is essential with community services continuing to grow in response to service need. 232 
However, a proportion of patients who have access to regular, high quality care also continue 233 
to deteriorate. It is therefore not surprising that patients followed in COGS still have a 234 
detectable rate of glaucoma progression.  235 
 236 
The overall median rate of deterioration of -0.3 dB/year in AGC and -0.1 dB/year in COGS is 237 
comparable to previous reports of glaucoma progression in UK secondary care(16), as is the 238 
proportion of patients progressing at a rate greater than 1 dB/year (14.2% in the AGC group). 239 
Our rates are lower than those reported from a large tertiary glaucoma service in Sweden 240 
(median -0.62 dB/year)(17) , although that population has a higher proportion of patients with 241 
pseudoexfoliation glaucoma who are known to have a higher risk of progression(18,19). 242 
Another factor contributing to this difference between centres may be that our data was 243 
extracted from either eye whereas the Lund authors used data from the eye with the greater 244 
visual field defect.  245 
 246 
Large multi-centre trials such as the Early Manifest Glaucoma Trial(19) and the United 247 
Kingdom Glaucoma Treatment Study(20) also found that a significant proportion of patients 248 




populations show normal tension in IOP measurements(21). In Japan, normal tension glaucoma 250 
(NTG) accounts for the majority of patients diagnosed with open-angle glaucoma(22). 251 
Although aggressively lowering the IOP by 30% has been shown to reduce the risk of 252 
progression for patients with NTG from 35% to 12 % over 5 years, this still means a large 253 
number of people will continue to lose vision despite best available current treatment.  254 
 255 
The reasons why retinal ganglion cell loss and corresponding visual field deterioration 256 
continues despite best treatment are currently unknown, but contributing factors may include 257 
insufficient IOP lowering with conventional treatment, poor compliance with intended therapy, 258 
or progression despite optimised IOP lowering treatment. A variety of approaches are being 259 
undertaken to tackle these problems, from the refinement of medical, laser and surgical 260 
approaches to lower the intraocular pressure(23–29), understanding genetic predisposition and 261 
the development of personalised medicine(30,31), to new sustained release drug-delivery 262 
devices(32) to minimise the effect of poor compliance and the development of neuroprotective 263 
strategies as an alternative or adjunct to IOP lowering therapies(33).  264 
 265 
Another consideration is the usefulness of OCT scanning in the assessment of glaucoma in the 266 
community setting. Abnormalities on OCT scanning of the optic nerve head in subjects over 267 
50 years have been reported to have a false positive glaucoma detection rate of 30%.(34) In 268 
another study, focal abnormalities of the retinal nerve fibre layer on spectral domain OCT 269 
scanning had a false positive rate of 35%.(35) Furthermore, each OCT technology has different 270 
analysis software which is not interchangeable between machines. We therefore did not 271 
mandate OCT in the community setting at the time the current scheme was established, 272 





For the future, artificial intelligence techniques are playing a key role and their integration into 275 
clinical practice has the potential to significantly improve our early detection of at-risk patients 276 
and enhance our understanding of the underlying pathophysiology of glaucomatous visual 277 
loss(36–38). More accurate endpoints to monitor disease progression and the effects of 278 
intervention will also be important(33,39). A number of functional outcome measures are being 279 
evaluated in the assessment of glaucoma patients in addition to visual field testing(40–44), 280 
from contrast sensitivity(45,46), electrophysiology(47), task completion or simulation(48,49) 281 
to patient reported experience of visual loss(50–52).  282 
 283 
COGS appears an effective scheme to help manage lower risk glaucoma patients in the UK 284 
environment where accredited optometric support can be developed outside of the hospital 285 
setting, which increases the capacity within HES to manage higher risk patients. COGS patients 286 
have a lower rate of visual field deterioration compared to patients seen in AGC. Effective 287 
communication between the community and tertiary schemes is essential to facilitate transfer 288 
of patients requiring further hospital management safely and efficiently.  289 
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Figure 1: Visual field loss and MD progression rate. A: Relationship between visual field loss 488 
at end of study and rate of MD progression in AGC patients. Spearman’s correlation 489 
coefficient r =0.60; p<0.0001. B: Relationship between visual field loss at end of study and 490 
rate of MD progression in COGS patients. Spearman’s correlation coefficient r =0.33; 491 
p<0.0001. C: Distribution of final MD D: Relationship between initial MD and rate of MD 492 
progression.  493 
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Figure 2: Loss of sight year (LSY) analysis A: Hedgehog plot for all AGC patients Ai:Stable 496 
AGC patients Aii: Slow AGC progressors Aiii: Moderate AGC progressors B: Hedgehog plot 497 
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Table 1 - The Cambridge Community Optometry Glaucoma Scheme (COGS) 
Risk  Guideline  Clinician  
Low  
Family history only/no glaucoma  
Discharge  OHT < 24 mmHg  
Glaucoma suspect unchanged over 3+ years  
Low  
Stable OHT and glaucoma suspect  
COGS  
 On/off treatment  
 Once baseline imaging completed in HES  
 Includes PDS/PXF  
POAG (MD < 12 dB), stable on 2 consecutive occasions. Can include post-trabeculectomy > 24 months  
 No dense lens opacity  
 Not on hospital transport or limited mobility  
Does not require OCT for definitive management  
Low  
As for community low risk but requires transport/community not possible due to mobility issues/if regular OCT 
required  
Virtual hospital clinic  
Low  Community returns for consideration of discharge  Consultant  
Moderate  Secondary glaucoma or OHT  COGS  
Risk  Guideline  Clinician  
Angle closure patients  
Stable moderate to advanced glaucoma (MD > 12 dB), stable on 2 occasions, can include post-
trabeculectomy > 12 months  
Only eye any diagnosis  
 No dense lens opacity  
 Not on hospital transport or limited mobility  
Does not require OCT for definitive management  
Moderate  Post-laser or medication change  AGC: nurse led  
Moderate  
Glaucoma progression is suspected  
AGC: doctor or optometrist 
clinics  
Pre- and post-cataract assessments in glaucoma patients  
Post-op trabeculectomy < 12 months but >2 months  
High  
Unstable advanced glaucoma  
AGC: consultant slot  For consideration of surgery  
Post-op trabeculectomy/tube/other (<2 months)  
 
Table 2 - Summary statistics 
 Tertiary (AGC)  Community (COGS)  
Number of eyes  362  210  
Number of patients  188  119  
Age, years (mean ± SEM)  74.8 (±0.80)  69.9 (±0.98)  
Gender, n (%)  
  Male  100 (53.2)  69 (57.9)  
  Female  88 (46.8)  50 (42.1)  
Median number of VF tests  7 (6–10)  6 (5–8)  
Median follow-up, years  8 (4–11)  5 (4–8)  
Baseline severity MD  
−2.43  −2.08  
(−5.8 to −0.8)  (−4.9 to −0.4)  
Diagnosis, n (%)  
  Primary open-angle glaucoma  194 (53.8)  140 (66.2)  
  Ocular hypertension  39 (10.9)  24 (11.3)  
  Primary angle closure glaucoma  24 (6.7)  0  
  Normal tension glaucoma  44 (12.0)  34 (16.4)  
  Glaucoma suspect  19 (5.3)  4 (1.9)  
  Secondary open-angle glaucoma  26 (7.2)  4 (1.9)  
  Neovascular glaucoma  3 (0.8)  2 (0.9)  
  Uveitic glaucoma  11 (3.1)  3 (1.4)  
  Juvenile onset glaucoma  1 (0.3)  0  
Table 3 - Distribution of MD progression rates 
 Tertiary (AGC)  Community (COGS)  
MD progression dB/yr  −0.3 (−0.7 to 0.0)  −0.1 (−0.4 to 0.1)  
Range  −6.3 to 1.1  −2.1 to 1.3  
−0.5 < x ≤ −0.1  134/362 (37.0%)  141/210 (67.1%)  
−1 < x ≤ −0.5  78/362 (21.5%)  27/210 (12.9%)  
−2 < x ≤ −1  40/362 (11.0%)  12/210 (5.7%)  
−3 < x ≤ −2  7/362 (1.9%)  1/210 (0.5%)  
−4 < x ≤ −3  1/362 (0.3%)  0/210 (0%)  
x ≤ −4  4/362 (1.1%)  0/210 (0%)  
Figure 1 - Visual field loss and MD progression rate 
 
A Relationship between visual field loss at end of study and rate of MD progression in AGC patients. 
Spearman’s correlation coefficient r = 0.60; p < 0.0001. B Relationship between visual field loss at 
end of study and rate of MD progression in COGS patients. Spearman’s correlation coefficient 
r = 0.33; p < 0.0001. C Distribution of final MD. D Relationship between initial MD and rate of MD 
progression.
Figure 2 – Loss of sight year (LSY) analysis 
 
A Hedgehog plot for all COGS patients: Ai stable COGS patients, Aii slow COGS progressors, Aiii 
moderate COGS progressors. B Hedgehog plot for all AGC patients: Bi stable AGC patients, Bii slow 
AGC progressors, Biii moderate AGC progressors Biv rapid AGC progressors. C LSY in AGC and COGS. 
D Correlation between initial MD and LSY (Spearman–s correlation coefficient r = −0.13; p = 0.04). 
